PURPOSE OF REVIEW: This article provides an overview for understanding the diagnosis, pathogenesis, and management of diabetic neuropathy. RECENT FINDINGS: New information about the pathogenesis of diabetic neuropathy continues to emerge, which will lead to identifying new drug targets. It is clear that the natural history of diabetic neuropathy is changing and the rate of progression is slowing. This is likely because of a combination of earlier diagnosis, improved glycemic management, and improved control of related complications such as hyperlipidemia and hypertension. Early diagnosis is critical, and small fiber neuropathy or subclinical diabetic neuropathy may be reversed or significantly improved with appropriate intervention. The American Academy of Neurology recently published guidelines for the treatment of painful diabetic neuropathy. SUMMARY: Diabetic neuropathy is common and can present with varied clinical presentations discussed in this article. Although treatment currently focuses on pain management, attention should be paid to potential risk factors for neuropathy. For example, glycemic control, hyperlipidemia, and hypertension should be managed with diet, exercise, and medications. Class I or II clinical studies indicate that pregabalin, duloxetine, amitriptyline, gabapentin, and opioids are effective in the management of diabetic neuropathic pain.
PURPOSE OF REVIEW: This article provides an overview for understanding the diagnosis, pathogenesis, and management of diabetic neuropathy. RECENT FINDINGS: New information about the pathogenesis of diabetic neuropathy continues to emerge, which will lead to identifying new drug targets. It is clear that the natural history of diabetic neuropathy is changing and the rate of progression is slowing. This is likely because of a combination of earlier diagnosis, improved glycemic management, and improved control of related complications such as hyperlipidemia and hypertension. Early diagnosis is critical, and small fiber neuropathy or subclinical diabetic neuropathy may be reversed or significantly improved with appropriate intervention. The American Academy of Neurology recently published guidelines for the treatment of painful diabetic neuropathy. SUMMARY:Diabetic neuropathy is common and can present with varied clinical presentations discussed in this article. Although treatment currently focuses on pain management, attention should be paid to potential risk factors for neuropathy. For example, glycemic control, hyperlipidemia, and hypertension should be managed with diet, exercise, and medications. Class I or II clinical studies indicate that pregabalin, duloxetine, amitriptyline, gabapentin, and opioids are effective in the management of diabetic neuropathic pain.
Authors: L Zilliox; A C Peltier; P A Wren; A Anderson; A G Smith; J R Singleton; E L Feldman; N B Alexander; J W Russell Journal: Neurology Date: 2011-03-22 Impact factor: 9.910
Authors: Rami Massie; Michelle L Mauermann; Nathan P Staff; Kimberly K Amrami; Jayawant N Mandrekar; Peter J Dyck; Christopher J Klein; P James B Dyck Journal: Brain Date: 2012-10 Impact factor: 13.501
Authors: Dan Ziegler; Phillip A Low; William J Litchy; Andrew J M Boulton; Aaron I Vinik; Roy Freeman; Rustem Samigullin; Hans Tritschler; Ullrich Munzel; Joachim Maus; Klemens Schütte; Peter J Dyck Journal: Diabetes Care Date: 2011-07-20 Impact factor: 19.112
Authors: Lisa M Mangus; Jamie L Dorsey; Rachel L Weinberg; Gigi J Ebenezer; Peter Hauer; Victoria A Laast; Joseph L Mankowski Journal: Toxicol Pathol Date: 2016-05-27 Impact factor: 1.902
Authors: Krish Chandrasekaran; Muragundla Anjaneyulu; Joungil Choi; Pranith Kumar; Mohammad Salimian; Cheng-Ying Ho; James W Russell Journal: Int Rev Neurobiol Date: 2019-06-08 Impact factor: 3.230
Authors: Peter D Creigh; Michael P McDermott; Janet E Sowden; Michele Ferguson; David N Herrmann Journal: J Neurol Sci Date: 2017-05-12 Impact factor: 3.181
Authors: Leonardo Catalano-Iniesta; María Carmen Iglesias-Osma; Virginia Sánchez-Robledo; Marta Carretero-Hernández; Enrique J Blanco; José Carretero; María José García-Barrado Journal: J Physiol Biochem Date: 2018-10-26 Impact factor: 4.158
Authors: Vesna Dermanovic Dobrota; Pero Hrabac; Dinko Skegro; Ranko Smiljanic; Savko Dobrota; Ingrid Prkacin; Neva Brkljacic; Kristijan Peros; Martina Tomic; Vesna Lukinovic-Skudar; Vanja Basic Kes Journal: Health Qual Life Outcomes Date: 2014-12-03 Impact factor: 3.186